The Franco-Austrian laboratory Valneva plans to deliver the first doses of its vaccine against Covid-19 in Europe in the second quarter of 2022, the company said in a press release.
Read also
Covid-19: Valneva plans to deliver its first vaccines to Europeans in the second quarter of 2022
Valneva's inactivated and adjuvanted vaccine, VLA2001, is currently being scrutinized by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency.
This committee sent the laboratory some additional questions at the end of February.
"Valneva now expects to receive a positive recommendation from the CHMP for conditional authorization of VLA2001 for primary vaccination in adults aged 18-55 in April 2022
," the company said.
Enough to allow delivery to European countries during the second quarter of this year.
The laboratory says it has signed an agreement with the European Commission
“for the supply of a maximum of 60 million doses”
over
two years, including 24.3 million in 2022. Valneva has already received authorization for emergency use of his vaccine in Bahrain, which bought him 1 million doses.
These will start shipping this month.
On the other hand, the United Kingdom terminated a contract in September for 100 million doses.
See also
Valneva up sharply after the success of its chikungunya vaccine
On the strength of these orders, the biotech, originally specializing in travel vaccines, expects solid growth for 2022, with sales forecast between 430 and 590 million euros (including 350 to 500 million for serum against Covid), subject to regulatory approvals.
In 2021, its turnover was 348.1 million.
Like Novavax and Sanofi, Valneva hopes to have a card to play with messenger RNA recalcitrants.
